安飞士巴吉集团(CAR)
搜索文档
AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market
Seeking Alpha· 2024-11-21 13:16
Autolus Therapeutics plc (NASDAQ: AUTL ) is a promising CAR T-cell biotech that recently received FDA approval for AUCATZYL. This is AUTL's main value driver, and it's indicated for relapsed or refractory B-cell precursor acute lymphoblastic leukemia [ALL]. Based onMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate ...
MOTORTREND NAMES MERCEDES-BENZ E-CLASS 2025 CAR OF THE YEAR
Prnewswire· 2024-11-20 21:00
– Mercedes-Benz's elegant midsize luxury car has outdone its competitors to secure MotorTrend's Golden Calipers for the second time in five years –LOS ANGELES, Nov. 20, 2024 /PRNewswire/ -- MotorTrend Group, a Warner Bros. Discovery company, announced today the Mercedes-Benz E-Class as its 2025 Car of the Year award winner. The new E-Class, available as both a sedan and wagon-crossover, claimed the top spot amongst competitors for its elegant, refreshed design, excellent performance, and technology. MOT ...
Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases
Benzinga· 2024-11-19 02:24
Over the weekend, Bristol Myers Squibb & Co BMY shared preliminary data from a Phase 1 study of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation Process for severe, refractory autoimmune diseases.Data were presented at the American College of Rheumatology 2024.Also Read: Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee IssueCC-97540 (BMS-986353) is an investigational CD19-targeted CAR T cell therapy that expresses ...
Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial
Prnewswire· 2024-11-18 21:20
公司临床试验进展 - 已对正在进行的复发性卵巢癌CAR - T疗法1期临床试验的第三组中的第一名患者进行给药剂量为100万CAR阳性细胞 是第一组剂量的10倍 [1] - 在前两组患者中未观察到剂量限制性毒性 第二组患者接受的CAR - T细胞剂量是第一组的三倍 在评估剂量限制性毒性的一个月等待期后 开始对第三组第一名患者进行给药 [2] 公司技术及试验相关情况 - 公司的FSHR介导的CAR - T技术靶向卵泡刺激素受体 该受体仅在卵巢细胞 肿瘤血管和某些癌细胞上表达 试验招募至少接受过两种先前疗法的复发性卵巢癌成年女性 旨在评估安全性 确定最大耐受剂量并监测疗效 [3] - 研究的主要研究者表示 由于在前两组患者中未观察到剂量限制安全性问题 已进入下一组评估更高剂量 希望证明CAR - T的耐受性 并对在实体瘤中看到疗效持乐观态度 还提到第一组中的一名患者在输注后一年多有相对稳定甚至轻微改善的情况 基于此提交了试验方案修正案以允许可能受益于额外剂量的患者 预计更高的细胞剂量会提高疗效 第二次剂量可能会进一步提高反应率和持久性 [4] 公司概况 - 公司是一家临床阶段的生物技术公司 专注于癌症的治疗和预防 其治疗组合包括与莫菲特癌症中心合作开发的卵巢癌免疫疗法项目 使用一种新型CAR - T技术 其疫苗组合包括与克利夫兰诊所合作开发的用于治疗和预防乳腺癌和卵巢癌的疫苗以及针对其他难治性癌症的疫苗 公司独特的商业模式是与世界著名研究机构在所有开发阶段合作 [5]
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
GlobeNewswire News Room· 2024-11-18 21:05
患者治疗情况 - 27岁非裔美国 - 亚洲女性患者患狼疮性肾炎超10年接受无氟达拉滨预处理和单剂量FT819治疗后达到临床缓解且无免疫抑制治疗 [1] - 患者初始病情严重治疗后无≥3级不良事件无CRS ICANS或GvHD且疲劳完全消除 [2] - 无氟达拉滨预处理和单剂量FT819治疗后外周CD19 + B细胞迅速消除B细胞恢复以幼稚型为主 [3] FT819研究情况 - FT819一期自身免疫研究评估安全性药代动力学和抗B细胞活性前三位患者无剂量限制毒性 [5] - 公司正在招募FT819一期自身免疫研究的第二治疗组 [6] 公司技术平台情况 - 公司iPSC产品平台结合多重工程和单细胞选择制造细胞产品克服细胞疗法制造局限 [7] 公司概况 - 公司是临床阶段生物制药公司致力于为患者带来iPSC衍生细胞免疫疗法 [8]
Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline
Prnewswire· 2024-11-14 22:00
Emerging leadership in allogeneic CAR-T for hematologic malignancies demonstrated by recent P-BCMA-ALLO1 Phase 1 data and new preclinical findings for P-CD19CD20-ALLO1 and P-CD70-ALLO1 Latest preclinical data on P-BCMACD19-ALLO1 demonstrates its potential as a next-generation allogeneic TSCM-rich CAR-T for both autoimmune diseases and oncologyAdvancing innovative strategies to overcome the unique challenges of applying CAR-T to solid tumorsVirtual R&D Day featuring partner Astellas Pharma and Poseida's lead ...
Avis Budget Stock Appreciates 12% Despite Earnings Miss in Q3
ZACKS· 2024-11-11 22:40
Avis Budget Group, Inc. (CAR) reported lower-than-expected third-quarter 2024 results.See Zacks Earnings Calendar to stay ahead of market-making news.Despite the earnings miss, the stock has gained 12% since the earnings release on Oct. 31, 2024.CAR’s earnings of $6.7 per share missed the Zacks Consensus Estimate by 22.2% and decreased 60.4% from the year-ago quarter’s actual. Total revenues of $3.5 billion missed the consensus estimate by 2.3% and declined 2.4% on a year-over-year basis.Avis Budget’s share ...
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
GlobeNewswire News Room· 2024-11-10 02:30
公司FT825/ONO - 8250产品相关临床及临床前数据 - 产品FT825/ONO - 8250在临床前研究中其H2CasMab - 2抗原结合域优先靶向肿瘤细胞表达的HER2 [1] - 在1期实体瘤研究中低剂量单药治疗组显示出良好安全性无剂量限制毒性等不良情况 3名患者治疗后外周血显示CAR - T细胞扩增且第8天维持激活状态 [1] - 公司总裁对1期低剂量组初步临床观察结果满意包括安全性产品扩展和CAR - T细胞激活状态维持同时新临床前数据显示其HER2抗原结合域的癌症选择性识别特征 [2] - 1期研究旨在评估FT825/ONO - 8250单药及与单克隆抗体疗法联合治疗晚期实体瘤患者的安全性药代动力学和活性目前正在进行第二剂量水平单药治疗和第一剂量水平联合治疗的患者招募 [2] - 3名预处理患者接受1亿细胞单药治疗后第8天观察到CAR - T细胞峰值扩增且细胞处于激活状态无耗竭迹象截至2024年10月25日数据显示耐受性良好无不良事件 [2] - 临床前数据表明FT825/ONO - 8250在体内外对HER2特异性抗肿瘤活性强对HER2 +正常细胞的细胞溶解靶向有限其肿瘤选择性归因于新的HER2靶向抗原结合域 [3] - 新的HER2靶向抗原结合域H2CasMab - 2与曲妥珠单抗相比能优先识别HER2的局部错误折叠和p95截断变体 [4] - FT825/ONO - 8250通过高亲和力非裂解CD16(hnCD16)Fc受体表现出强大的抗体介导细胞毒性(ADCC)与曲妥珠单抗协同增强对HER2 +肿瘤细胞的清除与西妥昔单抗协同实现对癌细胞表达的HER2和表皮生长因子受体(EGFR)的多抗原靶向 [4] 公司与Ono合作相关 - 公司与Ono合作开发FT825/ONO - 8250在美国和欧洲共同负责开发和商业化Ono在世界其他地区拥有独家开发和商业化权利双方还在进行针对未公开肿瘤相关抗原的实体瘤项目的临床前开发 [5] 公司iPSC产品平台相关 - 人类诱导多能干细胞(iPSCs)具有无限自我更新和分化为身体所有细胞类型的独特双重特性公司的iPSC产品平台将人类iPSCs的多重工程与单细胞选择相结合创建克隆主iPSC系 [6] - 公司利用克隆主iPSC系制造工程细胞产品可库存备用可与其他疗法联合使用并可能覆盖广泛患者群体公司的平台旨在克服与使用患者或供体细胞制造细胞疗法相关的众多限制且有超500项已授权专利和500项待批专利申请的知识产权组合支持 [6] 公司概况相关 - 公司是临床阶段的生物制药公司致力于为癌症和自身免疫疾病患者提供诱导多能干细胞(iPSC)衍生的细胞免疫疗法在创建多重工程主iPSC系以及制造和临床开发现货型iPSC衍生细胞产品方面处于领先地位其产品线包括iPSC衍生的自然杀伤(NK)细胞和T细胞产品候选物 [7]
Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting
GlobeNewswire News Room· 2024-11-09 05:01
Multiplexed-engineered, iPSC-derived CAR T Cell Targets Proteins Expressed on Cancer Cells in Response to Cellular Stress and Malignant Transformation Off-the-shelf Product Candidate Incorporates Novel Sword & Shield Technology Designed to Promote Functional Persistence without Conditioning Chemotherapy FT836 Preclinical Data Shows Robust Antigen-mediated Expansion, Functional Persistence, and Durable Anti-tumor Activity in the Presence of Alloreactive T Cells SAN DIEGO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- ...
Canadian Apartment Properties: Immigration Changes Spook Investors
Seeking Alpha· 2024-11-09 01:04
Note: All amounts discussed are in Canadian Dollars. Stock Prices refer to those on the TSX and not the OTC symbol. Canadian options are generally not accessible by USTrapping Value provides Covered Calls, and Preferred Stock Trader covers Fixed Income. The Covered Calls Portfolio is designed to provide lower volatility income investing with a focus on capital preservation. The fixed income portfolio focuses on buying securities with high income potential and heavy undervaluation relative to comparatives. L ...